70 related articles for article (PubMed ID: 30542516)
1. Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides.
Nakata J; Nakajima H; Hayashibara H; Imafuku K; Morimoto S; Fujiki F; Motooka D; Okuzaki D; Hasegawa K; Hosen N; Tsuboi A; Oka Y; Kumanogoh A; Oji Y; Sugiyama H
Oncotarget; 2018 Nov; 9(89):36029-36038. PubMed ID: 30542516
[TBL] [Abstract][Full Text] [Related]
2. Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides.
Fujiki F; Tsuboi A; Morimoto S; Hashimoto N; Inatome M; Nakajima H; Nakata J; Nishida S; Hasegawa K; Hosen N; Oka Y; Oji Y; Sogo S; Sugiyama H
Cancer Immunol Immunother; 2021 Jan; 70(1):253-263. PubMed ID: 32696072
[TBL] [Abstract][Full Text] [Related]
3. Identification of mouse helper epitopes for WT1-specific CD4
Nakajima H; Nakata J; Imafuku K; Hayashibara H; Isokawa K; Udaka K; Fujiki F; Morimoto S; Hasegawa K; Hosen N; Hashii Y; Nishida S; Tsuboi A; Oka Y; Oji Y; Sogo S; Sugiyama H
Cancer Immunol Immunother; 2021 Nov; 70(11):3323-3335. PubMed ID: 34272593
[TBL] [Abstract][Full Text] [Related]
4. Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy.
Yokota C; Kagawa N; Takano K; Chiba Y; Kinoshita M; Kijima N; Oji Y; Oka Y; Sugiyama H; Tsuboi A; Izumoto S; Kishima H; Hashimoto N
Cancer Immunol Immunother; 2022 Jan; 71(1):189-201. PubMed ID: 34089373
[TBL] [Abstract][Full Text] [Related]
5. Human CLEC9A antibodies deliver Wilms' tumor 1 (WT1) antigen to CD141
Pearson FE; Tullett KM; Leal-Rojas IM; Haigh OL; Masterman KA; Walpole C; Bridgeman JS; McLaren JE; Ladell K; Miners K; Llewellyn-Lacey S; Price DA; Tunger A; Schmitz M; Miles JJ; Lahoud MH; Radford KJ
Clin Transl Immunology; 2020; 9(6):e1141. PubMed ID: 32547743
[TBL] [Abstract][Full Text] [Related]
6. Enzyme-Linked Immunosorbent Spot Assay for the Detection of Wilms' Tumor 1-Specific T Cells Induced by Dendritic Cell Vaccination.
Higuchi Y; Koya T; Yuzawa M; Yamaoka N; Mizuno Y; Yoshizawa K; Hirabayashi K; Kobayashi T; Sano K; Shimodaira S
Biomedicines; 2015 Dec; 3(4):304-315. PubMed ID: 28536414
[TBL] [Abstract][Full Text] [Related]
7. Delayed-Type Hypersensitivity: An Excellent Indicator of Anti-tumor Immunity With Wilms' Tumor 1 (WT1) Dendritic Cell Vaccine Therapy.
Nagai H; Karube R
Cureus; 2023 Nov; 15(11):e49221. PubMed ID: 38143707
[TBL] [Abstract][Full Text] [Related]
8. Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer.
De Sanctis F; Dusi S; Caligola S; Anselmi C; Petrova V; Rossi B; Angelini G; Erdeljan M; Wöll S; Schlitter AM; Metzler T; Steiger K; Borok Z; Bailey P; Bauer A; Halin C; Boschi F; Giugno R; Canè S; Lawlor R; Corbo V; Scarpa A; Constantin G; Ugel S; Vascotto F; Sahin U; Türeci Ö; Bronte V
Immunity; 2024 May; ():. PubMed ID: 38749447
[TBL] [Abstract][Full Text] [Related]
9. WT1 Cancer Vaccine in Advanced Pancreatic Cancer: A Systematic Review.
Gugulothu KN; Anvesh Sai P; Suraparaju S; Karuturi SP; Pendli G; Kamma RB; Nimmagadda K; Modepalli A; Mamilla M; Vashist S
Cureus; 2024 Mar; 16(3):e56934. PubMed ID: 38665761
[TBL] [Abstract][Full Text] [Related]
10. Targeted eradication of gastric cancer stem cells by CD44 targeting USP22 small interfering RNA-loaded nanoliposomes.
Yang F; Zheng Z; Xue X; Zheng L; Qin J; Li H; Zhou Y; Fang G
Future Oncol; 2019 Jan; 15(3):281-295. PubMed ID: 30543303
[TBL] [Abstract][Full Text] [Related]
11. Enhanced immune reaction resulting from co-vaccination of WT1 helper peptide assessed on PET-CT.
Nakata J; Isohashi K; Morimoto S; Itou R; Kamiya T; Matsuura A; Nakajima H; Fujiki F; Nishida S; Hasii Y; Hasegawa K; Nakatsuka S; Hosen N; Tsuboi A; Oka Y; Kumanogoh A; Shibano M; Munakata S; Oji Y; Hatazawa J; Sugiyama H
Medicine (Baltimore); 2020 Sep; 99(39):e22417. PubMed ID: 32991475
[TBL] [Abstract][Full Text] [Related]
12. Impact of mature dendritic cells pulsed with a novel WT1 helper peptide on the induction of HLA‑A2‑restricted WT1‑reactive CD8+ T cells.
Kan S; Bito T; Shimabuku M; Taguchi J; Ohkusa T; Shimodaira S; Sugiyama H; Koido S
Int J Oncol; 2020 Oct; 57(4):1047-1056. PubMed ID: 32945369
[TBL] [Abstract][Full Text] [Related]
13. Decade-long WT1-specific CTLs induced by WT1 peptide vaccination.
Suwabe T; Shibasaki Y; Tamura S; Katagiri T; Fuse K; Ida-Kurasaki T; Ushiki T; Sone H; Narita M; Masuko M
Int J Hematol; 2024 Apr; 119(4):399-406. PubMed ID: 38427208
[TBL] [Abstract][Full Text] [Related]
14. Wilms' tumor 1 -targeting cancer vaccine: Recent advancements and future perspectives.
Ogasawara M
Hum Vaccin Immunother; 2024 Dec; 20(1):2296735. PubMed ID: 38148629
[TBL] [Abstract][Full Text] [Related]
15. Spatial immune composition of tumor microenvironment in patients with pancreatic cancer.
Zwart ES; van Ee T; Affandi AJ; Boyd LNC; Rodriguez E; den Haan JMM; Farina A; van Grieken NCT; Meijer LL; van Kooyk Y; Mebius RE; Kazemier G
Cancer Immunol Immunother; 2023 Dec; 72(12):4385-4397. PubMed ID: 37938368
[TBL] [Abstract][Full Text] [Related]
16. Adoptive cell therapy in paediatric extracranial solid tumours: current approaches and future challenges.
Zappa E; Vitali A; Anders K; Molenaar JJ; Wienke J; Künkele A
Eur J Cancer; 2023 Nov; 194():113347. PubMed ID: 37832507
[TBL] [Abstract][Full Text] [Related]
17. WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1.
Oji Y; Kagawa N; Arita H; Naka N; Hamada KI; Outani H; Shintani Y; Takeda Y; Morii E; Shimazu K; Suzuki M; Nishida S; Nakata J; Tsuboi A; Iwai M; Hayashi S; Imanishi R; Ikejima S; Kanegae M; Iwamoto M; Ikeda M; Yagi K; Shimokado H; Nakajima H; Hasegawa K; Morimoto S; Fujiki F; Nagahara A; Tanemura A; Ueda Y; Mizushima T; Ohmi M; Ishida T; Fujimoto M; Nonomura N; Kimura T; Inohara H; Okada S; Kishima H; Hosen N; Kumanogoh A; Oka Y; Sugiyama H
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672344
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma.
Kiryu S; Ito Z; Suka M; Bito T; Kan S; Uchiyama K; Saruta M; Hata T; Takano Y; Fujioka S; Misawa T; Yamauchi T; Yanagisawa H; Sato N; Ohkusa T; Sugiyama H; Koido S
BMC Cancer; 2021 Nov; 21(1):1197. PubMed ID: 34758773
[TBL] [Abstract][Full Text] [Related]
19. Distinct difference in tumor-infiltrating immune cells between Wilms' tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies.
Yokota C; Nakata J; Takano K; Nakajima H; Hayashibara H; Minagawa H; Chiba Y; Hirayama R; Kijima N; Kinoshita M; Hashii Y; Tsuboi A; Oka Y; Oji Y; Kumanogoh A; Sugiyama H; Kagawa N; Kishima H
Neurooncol Adv; 2021; 3(1):vdab091. PubMed ID: 34355173
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
